GLOW: A Research Reference Blend of BPC-157, TB-500, and GHK-Cu

GLOW is a research material: a single vial containing a lyophilized (freeze-dried) mixture of three synthetic peptides at defined masses — BPC-157 at 10 mg, TB-500 at 10 mg, and GHK-Cu at 50 mg, for a total of 70 mg of peptide solids per vial, each component specified at greater than or equal to 99% purity. It is co-formulated for convenience as a combined analytical reference standard, not as a finished product with any intended biological effect. The defining characteristic of GLOW, from a scientific-integrity standpoint, is what it is not: it is not a studied therapeutic combination. There is no published, peer-reviewed literature evaluating the BPC-157 + TB-500 + GHK-Cu combination as a single agent, so this page makes no blend-level efficacy, mechanism, or outcome claims and attaches no citation to the blend. The honest description is a reference standard combining three individually-studied components. Researchers using GLOW should treat it as a way to obtain three reference peptides in fixed, known proportions in one vial, with all interpretation of the underlying science done component by component.

BPC-157 is a synthetic 15-amino-acid pentadecapeptide (sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val; CAS 137525-51-0), also known as PL 14736 or Body Protection Compound 157, derived from a partial sequence within a protein identified in gastric juice. Its research record is almost entirely preclinical — rodent in-vivo injury models and in-vitro cell experiments — and the statements below describe what specific studies reported in defined experimental systems, not effects in humans. In tissue-repair models, BPC-157 has been studied for tendon, ligament, muscle, and gastrointestinal healing: rat studies report associations with improved ligament healing (Cerovecki et al., 2010, PMID 20225319), Achilles tendon-to-bone healing (Krivic et al., 2006, PMID 16583442), transected Achilles tendon healing with increased fibroblast outgrowth in vitro (Staresinic et al., 2003, PMID 14554208), and reduced muscle atrophy at a disabled myotendinous junction (Japjec et al., 2021, PMID 34829776). In gastric models, it was associated with dose-dependent reductions in ulcer formation (Xue et al., 2004, PMID 15052688). Proposed mechanisms drawn from these preclinical systems include modulation of angiogenesis via VEGF and the VEGFR2-Akt-eNOS axis (Brcic et al., 2009, PMID 20388964; Hsieh et al., 2017, PMID 27847966) and interaction with the nitric oxide system (Hsieh et al., 2020, PMID 33051481; Sikiric et al., 2014, PMID 23755725). Controlled human clinical data remain very limited, and BPC-157 is not an approved drug. A fuller treatment of the BPC-157 literature is maintained on its dedicated research overview.

TB-500 is a synthetic analogue of thymosin beta-4 (synonyms TB4, thymosin beta-4 fragment; component CAS 77591-33-4). It is one of the more extensively studied tissue-repair peptides in animal and cell-culture models, where it has been investigated in research contexts for angiogenesis, cell migration, keratinocyte migration, reduced scarring, and inflammatory resolution in wound and ischemic-tissue models. A recurring mechanistic theme in the published research is its actin-binding behavior: thymosin beta-4 sequesters monomeric G-actin through the conserved LKKTET actin-binding motif, a property frequently invoked when researchers discuss its association with cell migration and motility in experimental systems. These descriptions reflect observations reported in preclinical and in-vitro models; they are not statements about human outcomes, and there is no standardized clinical dosing for TB-500. To preserve research-use-only integrity and the rule against inventing citations, no PMID is attached to the TB-500 context above; researchers should consult the primary thymosin beta-4 literature directly. A fuller treatment of the thymosin beta-4 / TB-500 literature is available on the dedicated TB-500 research overview.

GHK-Cu is the glycyl-L-histidyl-L-lysine copper(II) complex — a copper-binding tripeptide (synonyms copper peptide, copper tripeptide; component CAS 49557-75-7). It carries roughly four decades of research, conducted in cell, animal, and some human topical studies, into skin regeneration, collagen and extracellular-matrix synthesis, wound-closure acceleration, angiogenesis, and antioxidant and gene-modulatory activity. The copper-binding character of the tripeptide is central to how this research is framed, with much of the literature exploring its role as a carrier of copper and its association with matrix remodeling and gene-expression changes in cultured cells and tissue models. As with the other components, these are descriptions of what investigators reported in laboratory systems, presented here only as research context — not as benefits, dosing, or any indication for human or veterinary use, and not as a property of the GLOW blend. Consistent with the no-fabrication rule, no PMID is attached to the GHK-Cu context above; the primary copper-peptide literature should be consulted directly. GHK-Cu does not currently have a dedicated research overview page on this site.

Because GLOW combines three peptides in one lyophilized vial, handling decisions affect all three components simultaneously, and the practical constraints follow the most sensitive component rather than the most robust. As supplied, GLOW is a lyophilized powder that should be treated as hygroscopic and protected from moisture, light, and heat; vials are typically kept frozen for long-term storage and brought to room temperature before opening to limit condensation. Reconstitution introduces an important multi-component caveat: the three peptides differ in physicochemical character — BPC-157 is a compact, acidic pentadecapeptide with no disulfide bridges, TB-500 is a larger acetylated peptide, and GHK-Cu is a small copper-coordinating tripeptide — so the choice of reconstitution solvent and buffer, as well as pH, can influence solubility and the integrity of the copper complex. Once reconstituted, peptide solutions are generally less stable than the lyophilized solid and are handled under refrigeration with attention to freeze-thaw cycles. Analytical confirmation (identity, purity, and content per component) is the appropriate way to verify a combined reference standard rather than assuming the labeled ratio. Detailed solvent, buffer, and stability guidance specific to this blend is documented separately on the GLOW storage and reconstitution guide and the GLOW chemistry data sheet. None of these handling notes imply any route of administration to humans or animals; they pertain solely to laboratory bench work with a research reference material.

GLOW and each of its three components are supplied strictly as reference compounds for in-vitro and laboratory research. None of BPC-157, TB-500, or GHK-Cu is an FDA-approved drug, and the GLOW blend is not an approved drug, dietary supplement, cosmetic, or article for human or veterinary use. The component research summarized on this page describes outcomes observed in preclinical and in-vitro systems — and, in the case of GHK-Cu, some human topical studies — but those observations do not constitute evidence of effect in people and are not provided as guidance for use. Where any component has been studied in humans, the accurate framing is that the compound was studied for a given endpoint in a defined research setting, never an instruction to use it. The GLOW combination itself has no clinical or preclinical efficacy data, and this page deliberately makes no blend-level claim. Investigators are responsible for handling, characterizing, and disposing of this material in accordance with applicable laboratory and institutional requirements.